medigraphic.com
ISSN 2221-2434 (Electronic)

2020, Number 4

<< Back Next >>

Finlay 2020; 10 (4)

Malignant pleural mesothelioma. Case report and literature review

Sánchez SS, Calvo DLM, Navarro BAL

Language: Spanish
References: 10
Page: 432-439
PDF size: 354.31 Kb.


ABSTRACT

Pleural mesotheliomas are primary mesothelial cell tumors. Lining the pleural cavity, they are closely related to asbestos exposure. They have a low incidence and poor prognosis. A 46-years-old patient, white-skinned, who attended the Dr. Gustavo Aldereguía Lima University General Hospital in Cienfuegos due to pain in the back and shoulders, fever, and weight loss is presented. The physical examination revealed an abolished vesicular murmur in the lower 1/3 of the right lung. The chest X-ray and CT scan showed a medium to large right pleural effusion and pleural thickening. Histological studies indicated that the lesion was compatible with epithelioid variant pleural mesothelioma. The patient is maintained with cytostatic treatment and follow-up in consultation. The objective of this study is to describe the case of a patient with malignant pleural mesothelioma, admitted to the Internal Medicine Service of the Dr. Gustavo Aldereguía Lima General University Hospital of Cienfuegos.


REFERENCES

  1. Light W. Trastornos de la pleura y el mediastino. En: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. Harrison. Principios de Medicina Interna. 19 ed. México DF: McGraw-Hill;2017. p. 2178-82.

  2. Antman KH. Malignant mesothelioma. N Engl J Med. 1990;303(1):200-02.

  3. Norbet C, Joseph A, Rossi SS, Bhalla S, Gutierrez FR. Asbestos-related lung disease: a pictorial review. Curr Probl Diagn Radiol. 2015;44(4):371-82.

  4. Bakhshayesh M, Karimi S, Mosadegh L, Chaibakhsh S. Malignant mesothelioma versus metastatic carcinoma of the pleura: a CT challenge. Iran J Radiol. 2016;13(1):e109494.

  5. Nickell LT, Lichtenberger JP, Khorashadi L, Abbott GF, Carter BW. Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma. Radiographics. 2014;34(6):1692-706.

  6. Gómez G, Collado JC. Mesotelioma pleural maligno. Actualización sobre diagnóstico y tratamiento. Rev Cubana Cir[Internet]. 2020[citado 5 Oct 2020];59(1):[aprox. 10p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-74932020000100009&lng=es. Epub 15-Jul-2020.

  7. Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health. 2013;34(1):205-16.

  8. Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015;16(4):447-56.

  9. Wong RM, Ianculescu I, Sharma S, Gage DL, Olevsky OM, Kotóva S, et al. Inmunotherapy for malignant pleural mesothelioma. Current status and future prospects. Am J Respir Cell Mol Biol. 2014;50(8):870-5.

  10. Hiddinga BI, Rolfo C, van Meerbeeck JP. Mesothelioma treatment: Are we on target? A review. J Adv Res. 2015;6(3):319-30.




2020     |     www.medigraphic.com